A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

NCT05766501 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

641

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infection

Interventions

DRUG: DOR/ISL

Sponsor

Merck Sharp & Dohme LLC